SafeScience starts Phase II cancer trial

SAFS started a U.S. Phase II study of GBC-590, a carbohydrate lectin inhibitor. The trial will assess safety, efficacy, and pharmacokinetics in patients with refractory or relapsing carcinoma of the p...